Media
Press Release
26
2024.03
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
20
2024.03
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
30
2024.01
Completion Of The first batch of subject enrollment in the Phase I clinical trial of the new adjuvant recombinant herpes zoster vaccine in China
23
2024.01
Recbio Enters a License and Strategic Cooperation with SPIMACO for Recombinant HPV-9 Vaccine in 15 countries in the Middle East and North Africa.
Publications
2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Download
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques